Free Trial
TSE:RVX

Resverlogix (RVX) Stock Price, News & Analysis

Resverlogix logo
C$0.06
-0.02 (-26.67%)
(As of 11/4/2024 ET)

About Resverlogix Stock (TSE:RVX)

Key Stats

Today's Range
C$0.06
C$0.06
50-Day Range
C$0.05
C$0.09
52-Week Range
C$0.04
C$0.10
Volume
70,073 shs
Average Volume
60,713 shs
Market Capitalization
C$15.23 million
P/E Ratio
N/A
Dividend Yield
7.02%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Receive RVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter.

RVX Stock News Headlines

10 EV Stocks to Buy Right Now
EV stocks are red hot. We’ve found TEN that we think will produce big wins for early investors. There’s no charge to view this report, so I urge everyone to check out the 10 stocks we’ve found as soon as possible.
Resverlogix Corp. (RVXCF)
Closing Bell: Resverlogix Corp up on Tuesday (RVX)
See More Headlines

RVX Stock Analysis - Frequently Asked Questions

Resverlogix's stock was trading at C$0.07 at the beginning of 2024. Since then, RVX stock has decreased by 21.4% and is now trading at C$0.06.
View the best growth stocks for 2024 here
.

Resverlogix Corp. (TSE:RVX) released its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.02) earnings per share for the quarter.

Shares of RVX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Antibe Therapeutics (ATE), Oncolytics Biotech (ONC), Radient Technologies (RTI), VentriPoint Diagnostics (VPT) and Burcon NutraScience (BU).

Company Calendar

Last Earnings
8/14/2024
Today
11/04/2024
Next Earnings (Estimated)
11/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Net Income
C$-10,740,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.00 per share
Book Value
C($0.28) per share

Miscellaneous

Free Float
N/A
Market Cap
C$15.23 million
Optionable
Not Optionable
Beta
0.71
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (TSE:RVX) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners